Highlight
- Ultrasensitive ctDNA detection effectively identifies minimal residual disease (MRD) in large B-cell lymphoma (LBCL) patients, outperforming traditional PET imaging in prognostic accuracy.
- Patients with undetectable ctDNA after frontline anthracycline-based chemotherapy show markedly higher progression-free survival (PFS) rates than those with detectable ctDNA.
- ctDNA-based remission assessment offers a refined biomarker for guiding clinical decisions and improving psychological reassurance in LBCL management.
Study Background and Disease Burden
Large B-cell lymphomas (LBCL) represent the most common aggressive non-Hodgkin lymphomas. Although many cases are curable with frontline anthracycline-based chemotherapy, relapse remains a major challenge, especially in patients harboring residual disease post-therapy. Traditional methods to evaluate remission, predominantly radiographic imaging such as PET scans, have limitations in sensitivity and specificity, which can lead to uncertainty in detecting minimal residual disease (MRD).
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker to detect MRD through non-invasive blood sampling. ctDNA originates from tumor cells undergoing apoptosis or necrosis, and its ultrasensitive detection may enable earlier and more precise identification of residual lymphoma cells, thereby refining remission assessment beyond conventional imaging. This could lead to improved prognostication and more personalized treatment strategies.
Study Design
This investigation pooled data from five prospective clinical trials (ClinicalTrials.gov: NCT04002947; NCT00398177; NCT02529852; NCT04231877; NCT04134936) involving patients with newly diagnosed LBCL receiving frontline anthracycline-based chemotherapy regimens. Pretreatment tumor tissue was sequenced to identify patient-specific tumor phased variants, which served as unique molecular tags for ctDNA tracking.
Serial plasma samples (totaling 409 specimens) were collected at defined landmark timepoints: after 2 cycles of chemotherapy and at the end of therapy. ctDNA detection was performed blinded, utilizing highly sensitive molecular assays targeting tumor-specific genomic variants, to assess MRD status.
The primary endpoint was progression-free survival (PFS), comparing patients with detectable versus undetectable ctDNA at respective timepoints. The prognostic value of ctDNA MRD was also compared to conventional PET-based response assessment.
Key Findings
The study included 137 patients with LBCL monitored over a median follow-up of 37 months. The proportion of patients with detectable ctDNA decreased substantially during treatment: 55% had undetectable ctDNA after 2 cycles, and 78% at the completion of therapy. This dynamic highlighted effective molecular remission in the majority with frontline chemotherapy.
Patients with undetectable ctDNA showed significantly improved outcomes. After 2 cycles, the 2-year PFS was 96% for undetectable ctDNA compared to 67% for those with detectable ctDNA (hazard ratio [HR] 6.9; p=0.0025). At the end of therapy, the difference was even more pronounced: 97% vs 29% 2-year PFS for undetectable versus detectable ctDNA groups (HR 28.7; p<0.0001).
Ninety-four percent of patients with undetectable ctDNA post-therapy remained alive without progression, contrasting starkly with 68% progression or death in patients with persistent ctDNA detection. Notably, MRD status via ctDNA had superior prognostic precision compared to PET scans—a positive PET scan yielded an HR of 3.6 for progression, whereas detectable ctDNA conferred an HR of 28.3.
These results validate ctDNA MRD as a robust and sensitive biomarker to predict relapse risk and long-term outcomes in LBCL.
Expert Commentary
This comprehensive integration of data across multiple prospective studies establishes a new paradigm for remission assessment in LBCL. By capturing tumor-specific phased variants, ctDNA assays provide unparalleled sensitivity to detect molecular residual disease. The stark differences in PFS according to ctDNA status underscore the biological relevance of residual circulating tumor-derived DNA as a surrogate for occult disease.
Unlike PET scans, which can be confounded by inflammation or metabolic activity unrelated to malignancy, ctDNA offers direct tumor genomic evidence, supporting its superiority as a prognostic tool. This could revolutionize monitoring strategies, enabling earlier interventions in high-risk patients and sparing low-risk patients the burden of overtreatment or unnecessary anxiety.
Nonetheless, challenges remain for broad implementation. Standardization of assay platforms, defining clinically meaningful ctDNA thresholds, and integrating MRD measurement with existing clinical risk factors are areas for ongoing research. Prospective trials incorporating ctDNA-guided therapeutic modifications are warranted to demonstrate improvements in survival and quality of life.
Conclusion
Ultrasensitive ctDNA detection post frontline therapy provides a precise, non-invasive biomarker that outperforms conventional radiographic criteria in assessing remission and predicting outcomes in large B-cell lymphoma. This advancement promises to refine clinical risk stratification, tailor treatment decisions, and improve both clinical and psychological outcomes. Future research should focus on clinical integration pathways and confirm the utility of ctDNA MRD for therapy guidance.
References
Roschewski M, Kurtz DM, Westin JR, Lynch RC, Gopal AK, Alig SK, et al. Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma. J Clin Oncol. 2025 Aug 13;101200JCO2501534. doi: 10.1200/JCO-25-01534. Epub ahead of print. PMID: 40802906; PMCID: PMC12363663.
Additional references supporting ctDNA utility in lymphoma:
1. Kurtz DM, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by sequencing of cell-free DNA. Blood. 2015;125(24):3679-3687.
2. Roschewski M, et al. Circulating tumor DNA and response dynamics in newly diagnosed diffuse large B-cell lymphoma. Blood. 2019;134(23):2039-2047.
These foundational studies provide background on the sensitivity of ctDNA tracking and its correlation with outcome in aggressive lymphomas.